Access and elimination: the future of DAAs in hepatitis C
Published in Pharmaphorum January 2017
The dramatic improvements in safety, efficacy, tolerability and convenience from the first wave of direct-acting antivirals (DAAs) have made a substantial contribution to changing both the treatment paradigm and the long-term prognosis for hepatitis C.
The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for some 700,000 deaths globally each year.
EphMRA One Day Meeting
We are delighted to be attending and presenting a paper at the EphMRA one day meeting on Tuesday 21st February, in London
Emerging markets expert Rachel Howard will be presenting the paper ‘Patient Willingness to Pay in the Real World’ from 14.35 - 15.05pm. A critical part of any self-paid healthcare product’s launch strategy is to set the right price, one which patients are willing to pay.
We were delighted to exhibit and present a paper at the Pharmaceutical Market Research Conference 1-2 February in Parsippany, NJ.
Tom Nolte, Head of Business Analytics (North America) and Melinda Shorr, Director, represented us at the conference. Tom presented the paper ‘Reinforcing the House: When Behavioral- and Attitudinal-Level Sources Strengthen Segmentation’.
How qualitative insights were used to help shift perceptions of the use of probiotics in IBS Management
Our client was planning to launch an over-the-counter (OTC) probiotics product for the purposes of improving IBS management and wanted to understand current perceptions, practices and usage amongst a range of healthcare professionals in emerging markets. They wanted to uncover potential leverage points to build a strong storyline and communication strategy for their product, which would encourage healthcare professionals to recommend its use to their patients.
Nutraceuticals in India: A Challenging Opportunity
Published in eyeforpharma December 2016 by Marc Yates
As growth begins to plateau in more established territories, attention is turning to emerging markets with a fast-expanding middle class. One of these is India. It cannot quite compete with China for sheer volume of potential consumers: China has a population of around 1.38 billion compared with 1.31 billion in India, although the Indian population is expected to catch up by 2022. On the other hand, a significantly larger proportion of the Chinese population lives in urban environments, where factors such as improved access to healthcare, higher disposable income and more exposure to diseases of affluence will create greater demand for nutraceuticals. Nonetheless, India offers considerable potential for growth from a modest base, currently estimated at 1-2% of global nutraceutical sales. To deliver fully on that promise, though, food and pharmaceutical companies need to address a number of regulatory, cultural, economic and structural challenges in the Indian market.